The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Interferon gamma-1b (Drug)
Phase: N/A
Status: Completed
Sponsored by: Amgen
Summary
To determine safety and tolerance of administering aerosolized recombinant interferon gamma
(IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages
by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of
IFN-gamma can activate alveolar macrophages in AIDS patients.
Clinical Details
Official title: Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS
Study design: Treatment, Safety Study
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- Diagnosis of AIDS with one or more opportunistic infections.
- Kaposi's sarcoma with prior history of opportunistic infection.
- Stable dose of zidovudine (AZT) therapy.
- Preserved pulmonary, renal and hepatic function.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Presence of active infection.
- Active opportunistic infections.
- Cardiac disease.
- Central nervous system disorders.
- History of seizures.
- Irreversible airway disease.
Patients with the following are excluded:
- Co-existing conditions and symptoms listed in Patient Exclusion Co-existing
Conditions.
Prior Medication:
Excluded within 4 weeks of study entry:
- Immunosuppressive therapy.
- Cytotoxic therapy.
- Excluded:
- Interferon gamma therapy.
Locations and Contacts
New York Hosp - Cornell Med Ctr, New York, New York 10021, United States
Additional Information
Last updated: June 23, 2005
|
